Oxygen‐dependent flow of sickle trait blood as an in vitro therapeutic benchmark for sickle cell disease treatments
- 21 August 2018
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 93 (10) , 1227-1235
Abstract
Although homozygous sickle cell disease is often clinically severe, the corresponding heterozygous state, sickle cell trait, is almost completely benign despite the fact that there is only a modest difference in sickle hemoglobin levels between the two conditions. In both conditions, hypoxia can lead to polymerization of sickle hemoglobin, changes in red cell mechanical properties, and impaired blood flow. Here, we test the hypothesis that differences in the oxygen‐dependent rheological properties in the two conditions might help explain the difference in clinical phenotypes. We use a microfluidic platform that permits quantification of blood rheology under defined oxygen conditions in physiologically sized microchannels and under physiologic shear rates. We find that, even with its lower sickle hemoglobin concentration, sickle trait blood apparent viscosity increases with decreasing oxygen tension and may stop flowing under completely anoxic conditions, though far less readily than the homozygous condition. Sickle cell trait blood flow becomes impaired at significantly lower oxygen tension than sickle cell disease. We also demonstrate how sickle cell trait can serve as a benchmark for sickle cell disease therapies. We characterize the rheological effects of exchange transfusion therapy by mixing sickle blood with nonsickle blood and quantifying the transfusion targets for sickle hemoglobin composition below which the rheological response resembles sickle trait. These studies quantify the differences in blood flow phenotypes of sickle cell disease and sickle cell trait, and they provide a potentially powerful new benchmark for evaluating putative therapies in vitro.Keywords
Funding Information
- American Heart Association (13SDG645000016PRE31020025, 13SDG6450000, 16PRE31020025)
- National Heart, Lung, and Blood Institute (HL114476R01HL132906R21HL130818 R56HL132906, R01HL132906, R56HL132906, R21HL130818)
- National Institutes of Health (DP2DK098087)
- Life Sciences Research Foundation
This publication has 53 references indexed in Scilit:
- A Biophysical Indicator of Vaso-occlusive Risk in Sickle Cell DiseaseScience Translational Medicine, 2012
- In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technologyJournal of Clinical Investigation, 2012
- Mortality in Sickle Cell Anemia in Africa: A Prospective Cohort Study in TanzaniaPLOS ONE, 2011
- Generation of oxygen gradients with arbitrary shapes in a microfluidic deviceLab on a Chip, 2009
- Statistical Dynamics of Flowing Red Blood Cells by Morphological Image ProcessingPLOS Computational Biology, 2009
- Sickle cell vasoocclusion and rescue in a microfluidic deviceProceedings of the National Academy of Sciences, 2007
- Alloimmunization in Sickle Cell Anemia and Transfusion of Racially Unmatched BloodNew England Journal of Medicine, 1990
- Oxygen binding by sickle cell hemoglobin polymersJournal of Molecular Biology, 1982
- Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobinsJournal of Molecular Biology, 1979
- Transfusion therapy for cerebrovascular abnormalities in sickle cell diseaseThe Journal of Pediatrics, 1976